Document is current
Any future updates will be listed below
-
Authors
Padilla, Marshall S. https://orcid.org/0000-0003-3607-790X
Mrksich, Kaitlin https://orcid.org/0009-0008-7971-2129
Wang, Yiming https://orcid.org/0000-0003-3657-6100
Haley, Rebecca M. https://orcid.org/0000-0001-7322-7829
Li, Jacqueline J. https://orcid.org/0000-0002-7849-5483
Han, Emily L. https://orcid.org/0009-0008-6276-7502
El-Mayta, Rakan https://orcid.org/0000-0002-5855-233X
Kim, Emily H.
Dias, Sofia https://orcid.org/0000-0001-8275-7880
Gong, Ningqiang https://orcid.org/0000-0002-9444-8505
Teerdhala, Sridatta V.
Han, Xuexiang https://orcid.org/0000-0003-0011-5222
Chowdhary, Vivek https://orcid.org/0000-0003-1277-0128
Xue, Lulu https://orcid.org/0000-0001-5719-1336
Siddiqui, Zain
Yamagata, Hannah M. https://orcid.org/0000-0002-9525-7102
Kim, Dongyoon
Yoon, Il-Chul
Wilson, James M. https://orcid.org/0000-0002-9630-3131
Radhakrishnan, Ravi https://orcid.org/0000-0003-0686-2851
Mitchell, Michael J. https://orcid.org/0000-0002-3628-2244
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (T90DE030854)
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 27 November 2024
First Online: 24 January 2025
Competing interests
: M.S.P. and M.J.M. have filed a patent application related to the structure of the BEND lipids and biological applications (U.S. Provisional Patent Appl. No. 63/373,793, filed August 29, 2022). J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies and Ceva Santé Animale. He has sponsored research agreements with Alexion Pharmaceuticals, Amicus Therapeutics, CBM, Ceva Santé Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE, and Passage Bio, which are licensees of Penn technology. JMW is an inventor on patents that have been licensed to various biopharmaceutical companies and for which he may receive payments. The remaining authors declare no competing interests
